- InvestInvestment SuiteExclusiveFeatures
- PlatformProduct SuiteFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnResourceInvesting GuideEvents
- Partner
- Support
Invest
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | 1.0 | - |
Min SIP Amount | ₹200 | - |
Expense Ratio | 2.44 | - |
NAV | ₹29.91 | - |
Fund Started | 08 Feb 2019 | - |
Fund Size | ₹84.15 Cr | - |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | - |
Risk
Very High
-
Rating
1.0
-
Min SIP Amount
₹200
-
Expense Ratio
2.44
-
NAV
₹29.91
-
Fund Started
08 Feb 2019
-
Fund Size
₹84.15 Cr
-
Exit Load
Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days.
-
Returns
1 Year | 46.79% | - |
3 Year | 18.71% | - |
5 Year | 23.21% | - |
1 Year
46.79%
-
3 Year
18.71%
-
5 Year
23.21%
-
Holding Analysis
Equity | 95.82% | - |
Cash | 4.18% | - |
Equity
95.82%
-
Cash
4.18%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.87% |
Piramal Pharma Ltd. | 7.26% |
Artemis Medicare Services Ltd. | 6.66% |
Torrent Pharmaceuticals Ltd. | 5.35% |
Syngene International Ltd. | 4.54% |
Glenmark Pharmaceuticals Ltd. | 4.47% |
Mankind Pharma Ltd. | 4.32% |
Neuland Laboratories Ltd. | 4.24% |
Cipla Ltd. | 4.19% |
Suven Pharmaceuticals Ltd. | 4.08% |
-
Fund Manager
Name | Karan Doshi | - |
Start Date | 31 Jul 2023 | - |
Name
Karan Doshi
-
Start Date
31 Jul 2023
-
About Fund
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | - |
Launch Date | 08 Feb 2019 | - |
Description
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.
-
Launch Date
08 Feb 2019
-
